Skip to content

Clinical observation on the hepatoprotective effect of Tori's Anti-Crime Formula on the liver function of middle and late-stage primary hepatocellular carcinoma

Clinical observation on the hepatoprotective effect of Tori's Anti-Crime Formula on the liver function of middle and late-stage primary hepatocellular carcinoma

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000686
Enrollment
Unknown
Registered
2026-03-23
Start date
2025-04-10
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cancer

Interventions

Sponsors

Dongguan Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Stage IIb-IIIb hepatocellular carcinoma in accordance with the diagnosis and staging in accordance with the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition) issued by the General Office of the National Health and Wellness Commission; 2) Liver function Child-Pugh classification A or B; 3) PS = 2 points; 4) Age between 18 and 70 years old; and 5) complete clinical data; and 6) Expected survival greater than 3 months; 7) Good compliance

Exclusion criteria

Exclusion criteria: 1) Those with chronic renal failure and severe respiratory failure; 2) those with combined severe cardiovascular and cerebrovascular diseases or active tuberculosis and other infectious diseases; 3) those with active recurrent cancer; 4) those suffering from mental disorders

Design outcomes

Primary

MeasureTime frame
Liver Function Rating;

Secondary

MeasureTime frame
Alanine Aminotransferase;Aspartate aminotransferase;Total Bilirubin;Unconjugated bilirubin;Albumin;Hyaluronic acid;Laminin;Type IV collagen;procollagen type III;Hepatic Fibrosis Index-4;AST/Platelet Ratio Index;Alpha-fetoprotein;carcinoembryonic antigen;Carbohydrate Antigen 19-9;Interleukin-1;Interleukin-6;Interleukin-8;Interferon-?;Tumor Necrosis Factor-alpha;KPS score;Liver cancer-related Chinese medicine symptom scoring;

Countries

China

Contacts

Public ContactZeXian Shi

Dongguan Hospital of Traditional Chinese Medicine

1228179156@qq.com15768999090

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Apr 4, 2026